| Q95492528 | Q95492528 |
| Q36944013 | 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. |
| Q37702702 | 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia |
| Q40593350 | 5-Hydroxymethylcytosine is an essential intermediate of active DNA demethylation processes in primary human monocytes |
| Q38164206 | 5-hydroxymethylcytosine: a new insight into epigenetics in cancer |
| Q38272312 | 5-hydroxymethylcytosine: a potential therapeutic target in cancer |
| Q98154704 | Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients |
| Q46332183 | Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies |
| Q24633944 | Acute depletion of Tet1-dependent 5-hydroxymethylcytosine levels impairs LIF/Stat3 signaling and results in loss of embryonic stem cell identity |
| Q37731158 | Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells |
| Q37226486 | Alterations of 5-hydroxymethylcytosine in human cancers |
| Q38096235 | An evolutionary perspective on chronic myelomonocytic leukemia. |
| Q37327706 | An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis |
| Q51804038 | Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. |
| Q92002003 | Changes in IDH2, TET2 and KDM2B Gene Expression After Treatment With Classic Chemotherapeutic Agents and Decitabine in Myelogenous Leukemia Cell Lines |
| Q37480308 | Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance |
| Q37931879 | Chromatographic methods for the analysis of oxidatively damaged DNA. |
| Q51139133 | Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. |
| Q26865671 | Connections between TET proteins and aberrant DNA modification in cancer |
| Q60585004 | Consequences of mutant TET2 on clonality and subclonal hierarchy |
| Q47252408 | Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity |
| Q39778970 | DNA cytosine hydroxymethylation levels are distinct among non-overlapping classes of peripheral blood leukocytes |
| Q36395976 | DNA methylation and hydroxymethylation in hematologic differentiation and transformation |
| Q58390463 | DNA methylation as a transcriptional regulator of the immune system |
| Q38834298 | DNA methylation in hematopoietic development and disease |
| Q52633239 | DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15- cells in early chronic-phase chronic myeloid leukemia. |
| Q28073970 | DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders |
| Q96172067 | DNMT3A and TET2 mutations reshape hematopoiesis in opposing ways |
| Q50216979 | Distinct roles for TET family proteins in regulating human erythropoiesis |
| Q38639828 | Driver mutations of cancer epigenomes. |
| Q26828777 | Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they? |
| Q38298238 | Epigenetic control of myeloid cell differentiation, identity and function. |
| Q39337306 | Epigenetic dysregulation of hematopoietic stem cells and preleukemic state |
| Q98513823 | Epigenomic analysis of Parkinson's disease neurons identifies Tet2 loss as neuroprotective |
| Q26778323 | Functions of TET Proteins in Hematopoietic Transformation |
| Q37191875 | Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia. |
| Q60919331 | Global distribution of DNA hydroxymethylation and DNA methylation in chronic lymphocytic leukemia |
| Q36622088 | Hydroxylation of 5-methylcytosine by TET2 maintains the active state of the mammalian HOXA cluster |
| Q41897344 | Hydroxymethylcytosine and demethylation of the γ-globin gene promoter during erythroid differentiation |
| Q26767183 | Hypoxia, Epithelial-Mesenchymal Transition, and TET-Mediated Epigenetic Changes |
| Q41828194 | IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas |
| Q38940260 | IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition |
| Q38379074 | Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways |
| Q33697252 | Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis |
| Q36969070 | Interplay between Metabolism and Epigenetics: A Nuclear Adaptation to Environmental Changes |
| Q89639659 | JAK2-negative acute monocytic leukemia with TET2 mutation in essential thrombocythemia with JAK2 mutation with literature review |
| Q33614862 | LC-MS-MS quantitative analysis reveals the association between FTO and DNA methylation |
| Q36352394 | Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation |
| Q35980967 | Loss of 5-Hydroxymethylcytosine Is an Independent Unfavorable Prognostic Factor for Esophageal Squamous Cell Carcinoma |
| Q41685506 | Loss of expression of 5-hydroxymethylcytosine in CD30-positive cutaneous lymphoproliferative disorders |
| Q36691624 | Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. |
| Q26823896 | Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation |
| Q41818692 | Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia |
| Q89143229 | Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome |
| Q36275124 | Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator |
| Q41872392 | Overlapping Requirements for Tet2 and Tet3 in Normal Development and Hematopoietic Stem Cell Emergence |
| Q49960497 | Prenatal Exposure to Mercury: Associations with Global DNA Methylation and Hydroxymethylation in Cord Blood and in Childhood |
| Q28085708 | Properties and biological roles of TET proteins during embryogenesis and in hematopoiesis |
| Q38129336 | Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia |
| Q28068541 | Role of TET enzymes in DNA methylation, development, and cancer |
| Q83141302 | Role of TET2 mutations in myeloproliferative neoplasms |
| Q36242646 | Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia |
| Q64252242 | TET Enzymes and 5hmC in Adaptive and Innate Immune Systems |
| Q35630033 | TET family proteins and their role in stem cell differentiation and transformation. |
| Q36197509 | TET proteins and 5-methylcytosine oxidation in hematological cancers |
| Q35021377 | TET proteins and the control of cytosine demethylation in cancer |
| Q39005258 | TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells. |
| Q91735717 | TET2 deficiency leads to stem cell factor-dependent clonal expansion of dysfunctional erythroid progenitors |
| Q37643944 | TET2 plays an essential role in erythropoiesis by regulating lineage-specific genes via DNA oxidative demethylation in a zebrafish model |
| Q99420796 | TET2 promotes anti-tumor immunity by governing G-MDSCs and CD8+ T-cell numbers |
| Q28511594 | Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice |
| Q89705147 | Ten-eleven translocation-2 affects the fate of cells and has therapeutic potential in digestive tumors |
| Q35944741 | Tet family proteins and 5-hydroxymethylcytosine in development and disease |
| Q102054000 | Tet2 at the interface between cancer and immunity |
| Q92038228 | The DNA methylation landscape in cancer |
| Q27002485 | The TET2 interactors and their links to hematological malignancies |
| Q38162038 | The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases |
| Q60455985 | The expansive reach of TET2 |
| Q36972667 | The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cells |
| Q38712988 | Turning the tide in myelodysplastic/myeloproliferative neoplasms |
| Q41418744 | Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium |